Lung Cancer

The presence of neuronal autoantibodies in patients with lung cancer, specifically small cell lung cancer and non–small cell lung cancer, appears to be associated with cognitive impairment.

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, highlight the importance of global registries before sharing their closing thoughts on NRG1 fusions and the future treatment landscape of lung cancer.

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

Practical considerations regarding the role of NRG1 fusions in lung cancer management and how that has been informed by the eNRGy1 global registry study.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, share insight and key takeaways from the eNRGy1 global registry study.

CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.

A review of data from the eNRGy1 global registry study, with deference to the efficacy of current therapies and clinicopathologic features.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.

With the combination of mobocertinib and T-DM1, potent preclinical efficacy was observed in lung cancer cells with HER2 exon 20 insertion mutations.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.

In the early days of the COVID-19 pandemic, patients with malignant pleural mesothelioma were more likely to be hospitalized or die from COVID-19 versus the overall population.

Patients with non–small cell lung cancer and small-cell lung cancer with bone metastases may benefit from extended dosing with zoledronic acid.

Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.

Experts review a preclinical study of the anti-HER3 monoclonal antibody seribantumab, used in cell lines and mouse models of solid tumors.

“We’re learning to understand how to leverage immunotherapy for a cure.”

Ferdinandos Skoulidis, MD, PhD, MRCP, details what he was most excited to learn about at 2021 ASCO.

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Pralsetinib was well tolerated, while demonstrating robust and durable anti-tumor activity when treating heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

“Using science to guide therapy…has dropped the death rate in lung cancer historically.”

The CheckMate-816 trial is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer.

CancerNetwork® spoke with Nikki Martin of the LUNGevity Foundation regarding the “No One Missed” campaign working to provide education and awareness to patients with lung cancer.

The Virtual Nodule Clinic artificial intelligence–powered clinical decision support tool was cleared by the FDA for detection of early-stage lung cancer in lung nodules detected by a CT scan.

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.